Analysis of Serum Endothelial Cell-Specific Molecule 1 (Endocan) Level in Type 2 Diabetes Mellitus With Acute ST-Segment Elevation Myocardial Infarction and its Correlation
Restricted accessResearch articleFirst published online January, 2017
Analysis of Serum Endothelial Cell-Specific Molecule 1 (Endocan) Level in Type 2 Diabetes Mellitus With Acute ST-Segment Elevation Myocardial Infarction and its Correlation
Endothelial cell-specific molecule 1 (ESM-1; endocan) is expressed by endothelial cells, and it can be overexpressed in diabetic patients. However, little is known concerning diabetic patients with acute ST-segment elevation myocardial infarction (STEMI). Therefore, we assessed serum ESM-1 level in patients having type 2 diabetes mellitus (T2DM) STEMI; 72 patients with DM (38 with and 34 without vascular disease) and 33 individuals as a control group were included. There was a significant difference in serum ESM-1 level between the T2DM group and the control group (P = .03). There was also a significant difference in serum ESM-1 level between the T2DM with STEMI group and newly diagnosed T2DM group without vascular disease (P = .01). In patients with T2DM, serum ESM-1 levels correlated positively with high-sensitivity C-reactive protein levels and the neutrophil to lymphocyte ratio (r = .321, P = .006 and r = .320, P = .006). Our findings suggest that serum ESM-1 level may be a novel endothelial dysfunction biomarker and it may be related to vascular disease in T2DM.
WildSRoglicGGreenASicreeRKingH. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053.
2.
HuangESLaiteerapongNLiuJYJohnPMMoffetHHKarterAJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251–258.
KoseMEmetSAkpinarTS. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727–731.
5.
AlrouqFAAl-MasriAAAl-DokhiLMAlregaieyKABayoumyNMZakareiaFA. Study of the association of adrenomedullin and basic-fibroblast growth factors with the peripheral arterial blood flow and endothelial dysfunction biomarkers in type 2 diabetic patients with peripheral vascular insufficiency. J Biomed Sci. 2014;21:94.
6.
ArmanYAkpinarTSKoseM. Effect of Glycemic Regulation on Endocan Levels in Patients With Diabetes: A Preliminary Study. Angiology. 2016;67(3):239–244.
7.
QiuCSuiJZhangQ. Relationship of Endothelial Cell-Specific Molecule 1 Level in Stress Hyperglycemia Patients With Acute ST-Segment Elevation Myocardial Infarction: A Pilot Study. Angiology. 2016;67(9):829–834.
8.
Executive summary: standards of medical care in diabetes--2010. Standards of medical care in diabetes–2010. Diabetes Care. 2010;33(suppl 1):s4–s10.
9.
ThygesenKAlpertJSJaffeAS. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581–1598.
10.
HuFB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–1257.
11.
XuYWangLHeJ; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–959.
12.
HamiltonSJWattsGF. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud.2013;10(2-3):133–156.
13.
LassallePMoletSJaninA. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–20464.
14.
BechardDGentinaTDeleheddeM. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276(51):48341–48349.
15.
BéchardDScherpereelAHammadH. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167(6):3099–3106.
16.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291–296.
17.
YangJYangQYuSZhangX. Endocan: a new marker for cancer and a target for cancer therapy. Biomed Rep. 2015;3(3):279–283.
18.
RochaSFSchillerMJingD. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115(6):581–590.
19.
MikkelsenMEShahCVScherpereelA. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. Crit Care. 2012;27(5):522. e11-e17.
20.
HatfieldKJLassallePLeivaRALindåsRWendelboeØBruserudØ. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology. 2011;16(6):351–356.
21.
TousoulisDPapageorgiouNAndroulakisE. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013;62(8):667–676.
22.
DinarelloCA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med. 2011;269(1):16–28.
23.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243(1):339–343.
24.
BaltaSMikhailidisDPDemirkolS. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–777.
25.
BechardDMeigninVScherpereelA. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37(5):417–425.
26.
BaltaIBaltaSDemirkolS. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–1070.
27.
IcliACureECureMC. Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology. 2016;67(8):749–755.
28.
RodriguesKFPietraniNTBoscoAA. Endocan: a new biomarker associated with inflammation in type 2 diabetes mellitus?Diabetes Metab Res Rev. 2015;31(5):479–480.
29.
NiralaBKPerumalVGohilNK. Glycated serum albumin stimulates expression of endothelial cell specific molecule-1 in human umbilical vein endothelial cells: Implication in diabetes mediated endothelial dysfunction. Diab Vasc Dis Res. 2015;12(4):290–297.
30.
BaltaSOzturkC. Endocan, Obstructive Sleep Apnea, and Vascular Risk. Angiology. 2016;67(4):305–306.
31.
CelıkTBaltaSKaramanM. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015;24(1):55–60.
32.
MarenziGCosentinoNCortinovisS. Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Am J Cardiol. 2015;116(12):1791–1797.
33.
HenriksboBDSchertzerJD. Is immunity a mechanism contributing to statin-induced diabetes?Adipocyte. 2015;4(4):232–238.
34.
TadzicRMihaljMVcevAEnnenJTadzicADrenjancevicI. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res. 2013;37(2-3):103–115.
